Skip to main
BLTE
BLTE logo

BLTE Stock Forecast & Price Target

BLTE Analyst Ratings

Based on 5 analyst ratings
Strong Buy
Strong Buy 60%
Buy 40%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Belite Bio Inc has demonstrated promising progress in its clinical trials, particularly with positive interim Phase 3 results for its lead asset, tinlarebant, targeting STGD1, which may enhance market interest in treating dry AMD and stimulate share appreciation in the coming 12-18 months. The ongoing Phase 3 trial for geographic atrophy (PHOENIX) has expanded its sample size, showcasing the company's commitment to robust clinical data collection, while growing investor attention following favorable updates indicates increasing market confidence. Furthermore, the company's receipt of multiple designations, including fast track and orphan drug status across various markets, supports a strong strategic position, enhancing the potential for successful commercialization of its innovative treatments.

Bears say

Belite Bio Inc has demonstrated a persistent challenge with operating losses, reporting a net loss of $36.1 million in 2024, and may not attain profitability for several years, increasing concerns about its financial stability. The potential for austerity measures and uncertainties in reimbursement policies driven by economic conditions could further impair the company's ability to generate revenue. Additionally, regulatory surprises and the volatile nature of patient spending due to external economic factors introduce significant risk and uncertainty to Belite Bio's future financial outlook.

BLTE has been analyzed by 5 analysts, with a consensus rating of Strong Buy. 60% of analysts recommend a Strong Buy, 40% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Belite Bio Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Belite Bio Inc (BLTE) Forecast

Analysts have given BLTE a Strong Buy based on their latest research and market trends.

According to 5 analysts, BLTE has a Strong Buy consensus rating as of Jul 2, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $71.60, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $71.60, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Belite Bio Inc (BLTE)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.